Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors

Biomaterials

Volumn 31, Issue 33, 2010, Pages 8732-8740

  Nie, Hemin ^a   Fu, Yilong ^a   Wang, Chi Hwa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chemotherapy; Drug delivery; In vivo; Microsphere; Paclitaxel; Suramin

Indexed keywords

ANIMAL EXPERIMENTS; APOPTOSIS; BRAIN TUMORS; CHARACTERISTIC SEQUENCE; CORE/SHELL; CORE/SHELL MICROSPHERES; CORE/SHELL STRUCTURE; DRUG RELEASE SYSTEM; ELECTROHYDRODYNAMIC ATOMIZATION; HYDROPHILIC PROPERTIES; IN-VITRO; IN-VIVO; INNER FLOW; MODIFIED METHODS; NUDE MICE; OUTER FLOW; PACLITAXEL; POLYMER MICROSPHERES; RELEASE PATTERN; RELEASE RATE; SINGLE-STEP; SURAMIN; TUMOR INHIBITION;

CELL CULTURE; CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY; ELECTROHYDRODYNAMICS; MICROSPHERES; TUMORS;

ANIMAL CELL CULTURE;

MICROSPHERE; PACLITAXEL; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; COAXIAL ELECTROHYDRODYNAMIC ATOMIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RELEASE; ENCAPSULATION; HUMAN; HUMAN CELL; HYDRODYNAMICS; HYDROPHILICITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BIOLOGICAL ASSAY; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PACLITAXEL; SUBCUTANEOUS TISSUE; SURAMIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 77957309675     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.07.080     Document Type: Article

References (38)

1. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
2. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899.
3. Geurin C., Olivi A., Weingart J.D., Lawson H.C., Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004, 22:27-73.
4. Brem H., Mahaley M.S., Vick N.A., Black K.L., Schold S.C., Burger P.C., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991, 74:441-446.
5. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., et al. Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: the Polymer-Brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
6. Domb A., Israel Z.H., Elmalak O., Teomim D., Bentolia A. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm Res 1999, 16:762-765.
7. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P.C., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 2003, 5:79-88.
8. Whitehead K., Shen Z., Mitragotri S. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J Control Release 2004, 98:37-45.
9. Kasper F.K., Seidlits S.K., Tang A., Crowther R.S., Carney D.H., Barry M.A., et al. In vitro release of plasmid DNA from oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release 2005, 104:521-539.
10. Little S.R., Lynn D.M., Puram S.V., Langer R. Formulation and characterization of poly(b-amino ester) microparticles for genetic vaccine delivery. J Control Release 2005, 107:449-462.
11. Kim J., Lee J.E., Lee S.H., Yu J.H., Lee J.H., Park T.G., et al. Designed fabrication of a multifunctional polymer nanomedical platform for simultaneous cancer-targeted imaging and magnetically guided drug delivery. Adv Mater 2008, 20:478-483.
12. Hu S.H., Chen S.Y., Liu D.M., Hsiao C.S. Core/single-crystal-shell nanospheres for controlled drug release via a magnetically triggered rupturing mechanism. Adv Mater 2008, 20:2690-2695.
13. Potineni A., Lynn D.M., Langer R., Amiji M.M. Poly (ethylene oxide)-modified poly (beta-amino ester) nanoparticles: a long-circulating pH-sensitive biodegradable system for paclitaxel delivery. J Control Release 2003, 86:223-234.
14. Ranganath S.H., Wang C.H. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 2008, 29:2996-3003.
15. Kruger E.A., Figg W.D. Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. Clin Cancer Res 2001, 7:1867-1872.
16. ®), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma. J Neurooncol 2006, 80:9-17.
17. Ahmed F., Pakunlu R.I., Brannan A., Bates F., Minko T., Discher D.E. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors by inducing apoptosis in proportion to accumulated drug. J Control Release 2006, 116:150-158.
18. Song S., Yu B., Wei Y., Wientjes M.G., Au J.L.S. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 2004, 10:6058-6065.
19. Niero A., Emiliani E., Monti G., Pironi F., Turci L., Valenti A.M., et al. Paclitaxel and radiotherapy: sequence-dependent efficacy - a preclinical model. Clin Cancer Res 1999, 5:2213-2222.
20. von Eckardstein K.L., Patt S., Kratzel C., Kiwit J.C.W., Reszka R. Local chemotherapy of F98 rat glioblastoma with paclitaxel and carboplatin embedded in liquid crystalline cubic phases. J Neurooncol 2005, 72:209-215.
21. Fang G.F., Chang B.S., Kim C.N., Perkins C., Thompson C.B., Bhalla K.N. ''Loop'' domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 1998, 58:3202-3208.
22. Rodi D.J., Janes R.W., Sanganee H.J., Holton R.A., Wallace B.A., Makowski L. Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxolbinding protein. J Mol Biol 1999, 285:197-203.
23. Cahan M.A., Walter K.A., Colvin O.M., Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994, 33:441-444.
24. Tishler R.B., Geard C.R., Hall E.J., Schiff P.B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992, 52:3495-3497.
25. Prados M.D., Schold S.C., Spence A.M., Berger M.S., Mcallister L.D., Mehta M.P., et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996, 14:2316-2321.
26. Chamberlain M.C., Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytoma. J Neurooncol 1999, 43:269-276.
27. Chang S.M., Kuhn J.G., Robins H.I., Schold S.C., Spence A.M., Berger M.S., et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 2001, 91:417-422.
28. Hempel G., Rube C., Mosler C., Wienstroer M., Wagner-Bohn A., Schuck A., et al. Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors. Anticancer Drugs 2003, 14(6):417-422.
29. Kemper E.M., van Zandbergen A.E., Cleypool C., Mos H.A., Boogerd W., Beijnen J.H., et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003, 9(7):2849-2855.
30. Gelderblom H., Verweij J., Nooter K., Sparreboom A., Cremophor E.L. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37(13):1590-1598.
31. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985, 29:265-273.
32. Coffey R.J., Leof E.B., Shipley G.D., Moses H.L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-28 cells. J Cell Physiol 1987, 1132:143-148.
33. Vaisman N., Gospodarowicz D., Neufeld G. Characterization of the receptors for vascular endothelial cell growth factor. J Biol Chem 1990, 256:19461-19466.
34. Minniti C.P., Maggi M., Helman L.J. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res 1992, 52:1830-1835.
35. Pesenti E., Sola K., Mongelli N., Grandi M., Spreattio F. Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992, 66:367-372.
36. Ponten J., Macintyre E.H. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968, 74:465-486.
37. Nie H., Khew S.T., Lee L.Y., Poh K.L., Tong Y.W., Wang C.H. Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery. J Control Release 2009, 138:64-70.
38. Lee L.Y., Wang C.H., Smith K.A. Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel. J Control Release 2008, 125:96-106.